基础医学与临床 ›› 2016, Vol. 36 ›› Issue (5): 706-710.

• 短篇综述 • 上一篇    下一篇

CAR-T细胞在肿瘤临床试验中的研究进展

白仲添,王海平,严俊,刘小军,周文策,李汛   

  1. 兰州大学第一医院
  • 收稿日期:2015-09-21 修回日期:2015-12-03 出版日期:2016-05-05 发布日期:2016-04-26
  • 通讯作者: 李汛 E-mail:lxdr21@126.com
  • 基金资助:
    甘肃省科技重大专项;甘肃省自然科学研究基金计划;甘肃省卫生行业计划项目;中央高校基本科研业务费专项资金重点项目;中央高校基本科研业务费专项资金

Research progress of CAR-T cells in tumor clinical trials

  • Received:2015-09-21 Revised:2015-12-03 Online:2016-05-05 Published:2016-04-26
  • Contact: Xun LI E-mail:lxdr21@126.com

摘要: 以嵌合型抗原受体(CAR)为基础的细胞治疗近年成为肿瘤生物治疗领域最亮丽的明星。尤其是靶向CD19分子的CAR-T细胞在B淋巴细胞恶性肿瘤的临床治疗中取得了良好的疗效。本文通过总结国内外CAR-T细胞的临床试验数据,对其临床疗效和潜在的不良反应进行统计分析,并就CAR-T细胞的发生、临床应用及存在的问题进行阐述。

关键词: 嵌合抗原受体, T细胞, 肿瘤, 临床试验

Abstract: Currently, chimeric antigen receptor, CAR-related cellular immunotherapy is venerated as the gorgeous star in tumor biotherapy. The CAR-T cell such as which targeted CD19 has obtained the good curative effect in conquering B lymphocyte malignancies. The latest CAT-T related references were collected and summarized to mainly analyse the data of clinical trial, clinical effects and potential adverse reaction treated with CAR-T.

Key words: Chimeric antigen receptor(CAR), T lymphocyte, tumor, clinical trial